Table 3.
Results of the base-case analysis comparing ixekizumab and secukinumab in biological disease-modifying antirheumatic drug-naïve patients with active psoriatic arthritis and concomitant moderate-to-severe psoriasis.
| Parameter | Ixekizumab | Secukinumab | Difference |
| Costs (year 2018 values) | |||
| Total costs | €153 901 | €156 559 | −€2658 |
| Treatment costs | €26 424 | €27 729 | −€1305 |
| Administration costs | €26 | €24 | €2 |
| Physician visit costs | €4141 | €4202 | −€61 |
| Monitoring costs | €797 | €706 | €92 |
| On treatment HAQ-DI/PASI-related costs | €4608 | €4115 | €494 |
| BSC costs | €117 904 | €119 784 | −€1880 |
| QALYs | |||
| Total QALYs | 9.175 | 9.082 | 0.093 |
BSC, best supportive care; HAQ-DI, Health Assessment Questionnaire‒Disability Index; PASI, Psoriasis Area Severity Index; QALYs, quality-adjusted life-years.